Harmony Biosciences Holdings Inc (NASDAQ: HRMY) kicked off on Tuesday, down -3.65% from the previous trading day, before settling in for the closing price of $34.24. Over the past 52 weeks, HRMY has traded in a range of $28.14-$41.61.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 550.98% over the past five years. While this was happening, its average annual earnings per share was recorded 25.17%. With a float of $43.48 million, this company’s outstanding shares have now reached $57.14 million.
Let’s look at the performance matrix of the company that is accounted for 268 employees. In terms of profitability, gross margin is 76.39%, operating margin of 26.7%, and the pretax margin is 26.84%.
Harmony Biosciences Holdings Inc (HRMY) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Harmony Biosciences Holdings Inc is 24.18%, while institutional ownership is 83.13%. The most recent insider transaction that took place on Mar 03 ’25, was worth 159,090. In this transaction CHIEF COMMERCIAL OFFICER of this company sold 4,869 shares at a rate of $32.67, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Officer proposed sale 4,869 for $33.85, making the entire transaction worth $164,816.
Harmony Biosciences Holdings Inc (HRMY) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.17% per share during the next fiscal year.
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) Trading Performance Indicators
Take a look at Harmony Biosciences Holdings Inc’s (HRMY) current performance indicators. Last quarter, stock had a quick ratio of 3.27. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.65. Likewise, its price to free cash flow for the trailing twelve months is 8.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.51, a number that is poised to hit 0.63 in the next quarter and is forecasted to reach 4.05 in one year’s time.
Technical Analysis of Harmony Biosciences Holdings Inc (HRMY)
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) saw its 5-day average volume 1.07 million, a positive change from its year-to-date volume of 0.67 million. As of the previous 9 days, the stock’s Stochastic %D was 57.43%. Additionally, its Average True Range was 1.51.
During the past 100 days, Harmony Biosciences Holdings Inc’s (HRMY) raw stochastic average was set at 18.60%, which indicates a significant decrease from 23.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.17% in the past 14 days, which was lower than the 58.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.20, while its 200-day Moving Average is $34.72. Nevertheless, the first resistance level for the watch stands at $34.05 in the near term. At $35.12, the stock is likely to face the second major resistance level. The third major resistance level sits at $35.65. If the price goes on to break the first support level at $32.46, it is likely to go to the next support level at $31.93. Assuming the price breaks the second support level, the third support level stands at $30.86.
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) Key Stats
The company with the Market Capitalisation of 1.89 billion has total of 57,346K Shares Outstanding. Its annual sales at the moment are 714,730 K in contrast with the sum of 145,490 K annual income. Company’s last quarter sales were recorded 201,270 K and last quarter income was 49,470 K.
